← Back to contracts

NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)

US · US National Center for Complementary and Integrative Health (NCCIH), National Institutes of Health (NIH) grant open #PAR-25-270
Response due Nov 13, 2026 · 00:00 UTC

Summary

The National Center for Complementary and Integrative Health (NCCIH), part of NIH/HHS, is funding early phase clinical trials focused on natural products. This is an R33 award mechanism, indicating it is a milestone-driven phase of research typically following an R61 exploratory/developmental phase. Applicants must propose and conduct a clinical trial investigating a natural product. The opportunity is open for submissions over a roughly two-year window, from December 2024 through November 2026.

What they want

Applicants must design and conduct an early phase clinical trial involving a natural product as the intervention. The R33 mechanism requires that specific milestones be met and that a clinical trial is required (not optional). Work encompasses trial design, participant enrollment, data collection, and reporting consistent with NIH clinical trial requirements under the PAR-25-270 funding opportunity announcement.
Deliverables
  • Early phase clinical trial protocol and execution
  • Milestone achievement reports per R33 requirements
  • Clinical trial registration (ClinicalTrials.gov)
  • Final research findings and NIH progress/final reports
Technical requirements
  • Clinical trial must involve a natural product as the intervention
  • R33 milestone-driven research phase required
  • Clinical trial is required (not optional) per announcement designation
  • Must comply with NIH clinical trial policies and reporting requirements

How they evaluate

  • NIH peer review (scientific and technical merit)
  • Milestone feasibility and clinical trial design rigor
  • Relevance to NCCIH natural products research priorities
Submission: Grants.gov electronic submission portal (federal grants application)

Risks & flags

  • Extremely long open window (nearly 2 years) with rolling submissions may indicate multiple award cycles rather than a single competitive award — applicants should verify specific submission due dates within the FOA
  • R33 mechanism typically requires prior R61 phase completion, which may limit eligible applicants to those already in the R61/R33 paired pipeline

Market context

inferred from NAICS
Professional, Scientific & Technical Services
NAICS 541711
US market size
$2.0T
Typical award
$25K – $50M
Typical buyers
All federal civilianDoDStates
Commonly required
8(a)WOSBSDVOSBPE/PMP

Sector-level estimate — full code lookup not yet in catalog.

NCCIH Natural Product Early Phase Clinical…
Due Nov 13
Onboard ↗